Teva Announces Launch of Generic Prometrium Capsules in the United States

Teva Pharmaceutical Industries Ltd. TEVA announced today the commercial launch of Progesterone Capsules, 100 & 200 mg, the AB-rated generic equivalent of Abbott Laboratories' Prometrium Capsules. The brand product had annual sales of approximately $197 million in the United States, based on IMS sales data. The product is indicated for the treatment of secondary amenorrhea due to a decrease in progesterone as well as in conjunction with estrogen-containing medications in postmenopausal women with a uterus.